ETNB 89Bio

89bio to Participate in the UBS Global Healthcare Conference

89bio to Participate in the UBS Global Healthcare Conference

SAN FRANCISCO, Nov. 05, 2024 (GLOBE NEWSWIRE) -- 89bio, Inc. (the “Company” or “89bio”) (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of liver and cardiometabolic diseases, today announced that the Company’s Management will participate in a fireside chat at the UBS Global Healthcare Conference on Tuesday, November 12, 2024 at 12:30 PM EST and participate in one-on-one investor meetings.

The webcast of the presentation will be accessible in the investor section of . A replay of the webcast will be available for approximately 30 days following the conference.

About 89bio

89bio is a clinical-stage biopharmaceutical company dedicated to the development of best-in-class therapies for patients with liver and cardiometabolic diseases who lack optimal treatment options. The company is in Phase 3 studies for its lead candidate, pegozafermin, for the treatment of metabolic dysfunction-associated steatohepatitis (MASH) and severe hypertriglyceridemia (SHTG). Pegozafermin is a specifically engineered, potentially best-in-class fibroblast growth factor 21 (FGF21) analog with unique glycoPEGylated technology that optimizes biological activity through an extended half-life. The company is headquartered in San Francisco. For more information, visit or follow the company on .

Investor Contact: 

Annie Chang 

89bio, Inc.





PJ Kelleher

LifeSci Advisors, LLC

617-430-7579

Media Contact: 

Sheryl Seapy

Real Chemistry



EN
05/11/2024

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on 89Bio

 PRESS RELEASE

89bio Reports Third Quarter 2024 Financial Results and Corporate Updat...

89bio Reports Third Quarter 2024 Financial Results and Corporate Updates – The Phase 3 ENLIGHTEN program in patients with non-cirrhotic (F2-F3) and compensated cirrhotic (F4) metabolic dysfunction-associated steatohepatitis (MASH) continues to enroll patients across both trials – – Topline data from the Phase 3 ENTRUST trial in patients with severe hypertriglyceridemia (SHTG) are expected in 2025 – – Strengthened the Board of Directors and Executive Leadership Team with the appointments of Charles McWherter, Ph.D. to the Board of Directors, Francis Sarena as Chief Operating Officer, and T...

 PRESS RELEASE

89bio to Participate in the UBS Global Healthcare Conference

89bio to Participate in the UBS Global Healthcare Conference SAN FRANCISCO, Nov. 05, 2024 (GLOBE NEWSWIRE) -- 89bio, Inc. (the “Company” or “89bio”) (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of liver and cardiometabolic diseases, today announced that the Company’s Management will participate in a fireside chat at the UBS Global Healthcare Conference on Tuesday, November 12, 2024 at 12:30 PM EST and participate in one-on-one investor meetings. The webcast of the presentation will be...

 PRESS RELEASE

89bio to Present New Analyses from ENLIVEN Phase 2b Pegozafermin Trial...

89bio to Present New Analyses from ENLIVEN Phase 2b Pegozafermin Trial in Metabolic Dysfunction-Associated Steatohepatitis (MASH) at AASLD The Liver Meeting® 2024 SAN FRANCISCO, Oct. 15, 2024 (GLOBE NEWSWIRE) -- 89bio, Inc. (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of liver and cardiometabolic diseases, today announced that new analyses of data from the Phase 2b ENLIVEN trial evaluating pegozafermin in patients with metabolic dysfunction-associated steatohepatitis (MASH) with fibros...

 PRESS RELEASE

89bio to Participate in the H.C. Wainwright 8th Annual MASH Investor C...

89bio to Participate in the H.C. Wainwright 8th Annual MASH Investor Conference SAN FRANCISCO, Sept. 30, 2024 (GLOBE NEWSWIRE) -- 89bio, Inc. (the “Company” or “89bio”) (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of liver and cardiometabolic diseases, today announced that the Company’s Management will participate in a fireside chat and one-on-one investor meetings at the H.C. Wainwright 8th Annual MASH Investor Conference on Monday, October 7, 2024 at 11:30 AM ET. The webcast of the ...

 PRESS RELEASE

89bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

89bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) SAN FRANCISCO, Sept. 19, 2024 (GLOBE NEWSWIRE) -- 89bio, Inc. (the “Company” or “89bio”) (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of liver and cardiometabolic diseases, today announced that the Compensation Committee of the Company’s Board of Directors approved the grant of non-qualified stock options to purchase an aggregate of 15,000 shares of the Company’s common stock to one new employee (the “Inducement Gra...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch